ULTRAGENYX PHARMACEUTICAL INC. Share-based Payment Arrangement, Amount Capitalized
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Share-based Payment Arrangement, Amount Capitalized of $2.78 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Notes › Share-Based Payment Arrangement
us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount · last filed 2025-11-05
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, amount capitalized for the quarter ending 2025-09-30 was -$30.00K, a 115.15% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, amount capitalized for the quarter ending 2025-06-30 was -$189.00K, a 186.70% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, amount capitalized for the quarter ending 2025-03-31 was $3.00M, a 7.65% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, amount capitalized for the quarter ending 2024-09-30 was $198.00K, a 23.55% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, amount capitalized for fiscal 2022 was $2.34M, a 61.05% increase from fiscal 2021.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, amount capitalized for fiscal 2021 was $1.45M, a 11.43% increase from fiscal 2020.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, amount capitalized for fiscal 2020 was $1.30M, a 8.13% increase from fiscal 2019.
- ULTRAGENYX PHARMACEUTICAL INC. share-based payment arrangement, amount capitalized for fiscal 2019 was $1.21M, a 13.99% increase from fiscal 2018.
| Period end | Share-based Payment Arrangement, Amount Capitalized 3 month | Share-based Payment Arrangement, Amount Capitalized 6 month | Share-based Payment Arrangement, Amount Capitalized 9 month | Share-based Payment Arrangement, Amount Capitalized 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$219.00K derived: sum of 2 quarters · filed 2025-11-05 | $2.78M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$189.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.81M 10-Q · filed 2025-08-06 | ||
| 2025-03-31 | $3.00M 10-Q · filed 2025-05-07 | |||
| 2024-09-30 | $198.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $416.00K derived: sum of 2 quarters · filed 2025-11-05 | $3.20M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $218.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $3.00M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $2.79M 10-Q · filed 2025-05-07 | |||
| 2023-09-30 | $259.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $286.00K derived: sum of 2 quarters · filed 2024-11-06 | $2.56M 10-Q · filed 2024-11-06 | $4.28M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $2.30M 10-Q · filed 2024-08-02 | $4.02M derived: sum of 3 quarters · filed 2024-08-02 | $2.82M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-03-31 | $2.28M 10-Q · filed 2024-05-03 | $4.00M derived: sum of 2 quarters · filed 2024-05-03 | $2.79M derived: sum of 3 quarters · filed 2024-05-03 | $3.04M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $513.00K derived: sum of 2 quarters · filed 2023-11-03 | $759.00K derived: sum of 3 quarters · filed 2023-11-03 | $2.34M 10-K · filed 2023-02-17 |
| 2022-09-30 | -$1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$962.00K derived: sum of 2 quarters · filed 2023-11-03 | $619.00K 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $246.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $1.83M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $1.58M 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | $1.45M 10-K · filed 2023-02-17 | |||
| 2020-12-31 | $1.30M 10-K · filed 2023-02-17 | |||
| 2019-12-31 | $1.21M 10-K · filed 2022-02-15 | |||
| 2018-12-31 | $1.06M 10-K · filed 2021-02-12 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-02-20 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |